|1.||Quan, Walter D Y: 10 articles (03/2014 - 10/2006)|
|2.||Kinoshita, Yoshikazu: 10 articles (04/2012 - 02/2003)|
|3.||Quan, Francine M: 9 articles (09/2012 - 10/2006)|
|4.||Bello, Alfonso E: 6 articles (07/2015 - 03/2012)|
|5.||Walker, Paul R: 6 articles (02/2011 - 10/2006)|
|6.||Kent, Jeffrey D: 5 articles (07/2015 - 03/2013)|
|7.||Holt, Robert J: 5 articles (07/2015 - 03/2013)|
|8.||Suleyman, Halis: 5 articles (02/2015 - 09/2007)|
|9.||Haruma, Ken: 5 articles (12/2010 - 01/2008)|
|10.||Quan, Walter: 5 articles (04/2010 - 12/2004)|
|1.||Duodenal Ulcer (Curling's Ulcer)
01/01/1990 - "Famotidine, a novel H2 receptor antagonist appears to be effective and well tolerated in the treatment of most patients with duodenal ulcer."
08/01/1992 - "is superior to 40 mg famotidine nocte in duodenal ulcer healing."
01/01/1988 - "Multicenter studies examining the efficacy of famotidine in reducing the incidence of duodenal ulcer recurrence showed that famotidine was superior to placebo at all intervals examined. "
03/01/1989 - "1) famotidine appears to be an effective and safe therapy for duodenal ulcer treatment; 2) it seems to act not only by inhibiting gastric acid secretion but also influencing some parameters related to the gastric mucosal barrier."
01/01/1988 - "Famotidine appears to be an effective treatment for acute duodenal ulcer. "
01/01/1992 - "In this study famotidine turned out to be very effective in ulcer healing and was free of side effects. "
01/01/1993 - "Famotidine 40 mg at bedtime healed 63 (89%) of the 71 ulcers at 8 weeks; the healing rate for NSAID/ASA-associated ulcers was 46 (96%) of 48, which was significantly greater than that for idiopathic ulcers (17 of 23; 74%) (P = 0.0119). "
10/01/1999 - "pylori positive during the study and the ulcer recurred in five of these patients (6.6%) despite continuous famotidine treatment. "
01/01/1985 - "By the end of the study, 97% of the ulcers were healed in the famotidine group compared to 66% in the placebo group (p less than 0.01). "
04/01/1984 - "A plasma level of YM-11170 required for 50% inhibition of stimulated acid secretion was found to be 13 ng/ml. These results indicate that YM-11170 is a very potent inhibitor of gastric acid secretion and that twice daily medication of 20 mg YM-11170 is recommendable for further antisecretory studies with ulcer patients."
|3.||Stomach Ulcer (Gastric Ulcer)
01/01/1987 - "The findings show that the new H2-receptor antagonist famotidine, administered as a single evening dose, significantly speeds the healing of benign gastric ulcers and that it is a safe and highly effective treatment of gastric ulceration. "
10/24/1986 - "Analysis of data from 15 countries has shown that famotidine is more effective than placebo in treating gastric ulcers. "
04/01/1991 - "A multicentre, double-blind, randomized, placebo-controlled trial was undertaken to investigate the therapeutic efficacy of a nocturnal dose of famotidine 20 mg to reduce the 1 year relapse rate of recently healed gastric ulcers. "
10/01/1989 - "As shown in placebo-controlled trials, famotidine is effective in healing both duodenal and gastric ulcers. "
01/01/1992 - "Famotidine therefore proved effective in the treatment of gastric ulcer and was well tolerated on a short term basis."
|4.||Peptic Ulcer (Peptic Ulcers)
10/01/1994 - "Twice daily administration of 0.5 mg/kg famotidine for 8 weeks appears to be a tolerated and effective treatment of children with gastroduodenal ulcers."
07/01/2009 - "The study aim was to evaluate the efficacy of famotidine in Japanese patients with peptic ulcers; it was analyzed the pooled data from previously conducted clinical trials in Japan. "
08/01/1996 - "In that study, the maximal dosage of famotidine was limited to 40 mg/day, the recommended maximal dosage for the treatment of peptic ulcer disease. "
01/01/1993 - "Our study shows that the pharmacokinetics of famotidine in patients with reflux oesophagitis is comparable to that in healthy volunteers and peptic ulcer patients. "
04/01/2014 - "Famotidine (FM) is a potent H2-receptor antagonist used for the treatment of peptic ulcer. "
|5.||Gastroesophageal Reflux (GERD)
04/01/1995 - "It is concluded that in patients with non-erosive gastro-oesophageal reflux disease famotidine therapy, 20 mg twice daily, is highly effective in reducing reflux disease symptoms."
02/01/1992 - "Famotidine is a very useful H2-receptor antagonist for the treatment of most patients with GERD."
11/01/1995 - "For maintenance treatment of GERD, famotidine 20 mg BID and 40 mg BID are more effective than placebo in extending the time in remission."
09/01/2009 - "Children whose asthmatic symptoms improved with famotidine were included in a GERD group. "
05/01/2003 - "To evaluate the safety and efficacy of famotidine for infant gastro-oesophageal reflux disease. "
|4.||Histamine (Histamine Dihydrochloride)
|1.||Drug Therapy (Chemotherapy)
|2.||Artificial Respiration (Mechanical Ventilation)
|5.||Complementary Therapies (Alternative Medicine)